In the lead-up to BIO, Cartherics’ COO, Dr Ian Nisbet was interviewed by BioSpectrum Asia to discuss the company’s innovative approach to cell therapy development. He discusses the transformative potential of CAR-NK cell therapies in treating solid tumours and endometriosis. These engineered natural killer cells, derived from iPSCs, are designed to target and eliminate cancer cells, offering a promising avenue for patients with limited treatment options.

Cartherics’ clinical development plans incorporate accelerated approval as an integral part of its strategy to minimize development timelines and costs, balanced with assuring patient safety.  Small biotech companies like Cartherics do not have the resources to investigate the myriad of dose, schedule, combination therapy and patient populations that could be explored with a new cell therapy.  The critical thing is to get an initial approval as quickly as possible and then let the product be explored by oncologists in the real-world setting.

Dr Nisbet also discusses the company’s novel approach using its CAR-NK cell therapy to develop treatments for endometriosis and the scientific and manufacturing hurdles in developing cell therapies. His insights underscore the significant strides being made in immunotherapy and the hope it brings to those affected by these challenging conditions.

Read the interview here: https://biospectrumasia.com/news/89/26202/cartherics-coo-dr-ian-nisbet-on-the-promise-of-car-nk-cells-for-cancer-and-endometriosis-at-bio-2025.html